·
October 21, 2017—ADVANCES IN DIAGNOSTICS Fabio Almeida, M.D.
As Medical Director of Phoenix Molecular Imaging and Southwest PET/CT Institute in Yuma, AZ, Dr. Almeida oversees clinics in Phoenix, Yuma, and Tucson, providing his extensive clinical expertise in PET/CT imaging. He continues his research, focused on applied medical informatics with emphasis on imaging and networking systems, optimization of fusion technology, and volumetric tumor assessment for radiation therapy planning. He actively participates in several oncology and neurologic clinical trials and is the principal investigator for a novel Carbon-11 PET agent for prostate cancer imaging.
October 21, 2017—ADVANCES IN DIAGNOSTICS Fabio Almeida, M.D.
As Medical Director of Phoenix Molecular Imaging and Southwest PET/CT Institute in Yuma, AZ, Dr. Almeida oversees clinics in Phoenix, Yuma, and Tucson, providing his extensive clinical expertise in PET/CT imaging. He continues his research, focused on applied medical informatics with emphasis on imaging and networking systems, optimization of fusion technology, and volumetric tumor assessment for radiation therapy planning. He actively participates in several oncology and neurologic clinical trials and is the principal investigator for a novel Carbon-11 PET agent for prostate cancer imaging.
previously:
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------·
November 18, 2017—ADVANCES IN IMMUNE THERAPY Richard Lam M.D.
A board-certified internist and oncologist, Richard Lam, MD, has been specializing full time at Prostate Oncology Specialists in the treatment of prostate cancer since 2001. He is the director of clinical research. Dr. Lam has written numerous articles based on his research. He is an active member of the American Society of Clinical Oncology and the American Society of Hematology. Dr. Lam continues to promote prostate cancer awareness and education by giving lectures at various medical conferences and prostate support groups throughout the country. He is particularly interested in utilizing state-of-the-art therapeutics for advanced prostate cancer.
A board-certified internist and oncologist, Richard Lam, MD, has been specializing full time at Prostate Oncology Specialists in the treatment of prostate cancer since 2001. He is the director of clinical research. Dr. Lam has written numerous articles based on his research. He is an active member of the American Society of Clinical Oncology and the American Society of Hematology. Dr. Lam continues to promote prostate cancer awareness and education by giving lectures at various medical conferences and prostate support groups throughout the country. He is particularly interested in utilizing state-of-the-art therapeutics for advanced prostate cancer.
previously:
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------·
· December—no meeting, next meeting in January.
No comments:
Post a Comment